News | April 30, 2013

Cost-Effective Prostate Cancer Treatment Underused in the United Kingdom

April 30, 2013 — Better outcomes can be achieved for prostate cancer patients by using brachytherapy, a highly targeted form of radiotherapy, compared to surgery, says the finding of a new clinical study conducted by Panaxea International, University of Twente, the Netherlands.[1] The study, presented at the European Society for Radiotherapy and Oncology (ESTRO) in April, used the latest cost-effectiveness model to look at relevant recent data for prostate cancer. The study analyzed research findings from six recent overview studies involving 55,000 patients, and looked at disease progression, associated costs and outcomes extrapolated over a 10-year time horizon from a U.K. National Health Service (NHS) cost perspective. The study authors found that in patients where the prostate cancer remains localized, brachytherapy is more cost-effective and, importantly, offers better quality of life outcomes — either when used alone in low-risk patients where active surveillance is not favored or in combination with external beam radiation therapy (EBRT) for higher-risk patients.[1]

Brachytherapy is a highly targeted form of radiotherapy where a radiation source is placed inside or next to the area that requires treatment. By doing so, it reduces the risk of unnecessary damage to healthy tissue and organs, and reduces side effects such as incontinence and erectile dysfunction. [2] Brachytherapy is underused in the United Kingdom, where only 4 to 5 percent of patients are treated with it, compared to 8 percent in Germany and 25 percent in the United States.[3]

Around 50 percent of prostate cancer patients in the United Kingdom are treated using surgery[4], which is associated with an increased risk of incontinence and impotence compared to radiotherapy treatments.[2] Despite the increased risk, more younger men choose surgery over radiotherapy, with studies showing that this treatment choice is influenced by the patient's first consultation with their doctor.[2]

"Prostate cancer is the most common cancer in men[5], and U.K. survival rates are lower than in comparable countries such as Norway and Sweden[6]," said Lotte Steuten, associate professor of health technology assessment at University of Twente and the lead author of the study. "Brachytherapy is offered as an outpatient procedure, which means it has shorter recovery time than surgery, and our findings reflect that it is more cost-effective.[1] We would urge all practitioners involved in the care of people with prostate cancer to consider these results and how they can achieve the best outcomes for their patients as well as cost-effectiveness for the healthcare system compared to other treatments excluding active surveillance."

Dr. Christine Elwell, consultant oncologist at Northampton General Hospital in Northampton, U.K., said, "In the past 20 years we have made huge strides in prostate cancer survival. But we can't and shouldn't lose sight of quality of life. This long-term analysis joins a growing body of evidence that brachytherapy should be considered in more cases and can improve outcomes."

The study was funded by a research grant provided by Elekta.

For more information: www.elekta.com


References:

1. Steuten LMG. "Comparative cost / QALY of guideline-recommended prostate cancer treatments: a UK cost perspective." PD 0371; 2nd ESTRO Forum, Geneva, Switzerland 2013.

2. Prescrire Int. 2012 Oct;21(131):242-8.

3. Guedea F et al, Radiother. Onc. 2007; 82: 50-54

4. Buron C et al, Int J Radiat Oncol Biol Phys 2007;67(3):812-22.

5. Prostate Cancer UK Available at: http://prostatecanceruk.org/information/prostate-cancer-facts-and-figures [last accessed March 2013]

6. A comparison of prostate cancer survival in England, Norway, Sweden www.ncin.org.uk/view.aspx?rid=284 [last accessed March 2013]

Related Content

ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Delphinus Enrolls First Patient in Discover Breast Ultrasound Clinical Project
News | Ultrasound Womens Healthcare | September 08, 2017
September 8, 2017 — Delphinus Medical Technologies Inc.
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Musculoskeletal Extremity Imaging in Medicare Beneficiaries Increased Over Two Decades
News | Orthopedic Imaging | September 06, 2017
A new study by the Harvey L. Neiman Health Policy Institute found that in the Medicare population, the utilization...
Overlay Init